Please select the option that best describes you:

How does your management change for patients with bone marrow failure due to a metastatic solid tumor to the marrow?   

Do you offer EPO and TPO support? Do you modify your systemic therapy up front or after subsequent cycles?



Answer from: Medical Oncologist at Academic Institution
Comments
Medical Oncologist at University of Minnesota
I agree with @Apar Kishor Ganti for the small cell...
Sign in or Register to read more